I have written several articles pertaining to a new class of cholesterol controlling medicines called CETP (cholesterol ester transfer protein) inhibitors.
CETP inhibitors can markedly raise good HDL cholesterol and moderately lower bad LDL. Most recently, all my articles have been negative given that the most clinically tested drug of this class called torcetrapib (developed by Pfizer) proved to be more harmful than beneficial. Torcetrapib markedly raised HDL, modestly lowered LDL, but...
